DF Dent & Co. Inc. Cuts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

DF Dent & Co. Inc. decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 218,304 shares of the medical research company’s stock after selling 6,475 shares during the period. Thermo Fisher Scientific accounts for 1.4% of DF Dent & Co. Inc.’s holdings, making the stock its 27th biggest position. DF Dent & Co. Inc. owned 0.06% of Thermo Fisher Scientific worth $113,568,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Howard Capital Management Group LLC grew its stake in shares of Thermo Fisher Scientific by 0.5% during the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock worth $33,759,000 after acquiring an additional 286 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Thermo Fisher Scientific by 22.1% in the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company’s stock worth $771,876,000 after purchasing an additional 225,568 shares in the last quarter. HighTower Advisors LLC increased its stake in Thermo Fisher Scientific by 3.8% during the 3rd quarter. HighTower Advisors LLC now owns 182,450 shares of the medical research company’s stock valued at $112,796,000 after purchasing an additional 6,709 shares in the last quarter. Integrated Wealth Concepts LLC raised its holdings in shares of Thermo Fisher Scientific by 19.1% in the third quarter. Integrated Wealth Concepts LLC now owns 5,677 shares of the medical research company’s stock worth $3,512,000 after buying an additional 912 shares during the last quarter. Finally, Ingalls & Snyder LLC lifted its stake in shares of Thermo Fisher Scientific by 12.3% during the third quarter. Ingalls & Snyder LLC now owns 1,347 shares of the medical research company’s stock worth $833,000 after buying an additional 147 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. This represents a 1.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a research note on Friday, January 31st. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research note on Friday, January 10th. Finally, Bank of America reduced their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Trading Up 1.3 %

Shares of TMO stock opened at $489.25 on Thursday. Thermo Fisher Scientific Inc. has a 1-year low of $475.27 and a 1-year high of $627.88. The firm has a market cap of $184.57 billion, a PE ratio of 29.60, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The company has a 50-day moving average of $536.85 and a two-hundred day moving average of $549.69. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a $0.43 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.35%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.41%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.